- Home
- SB vs ERAS Comparison
SB vs ERAS Comparison
Compare SB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- ERAS
- Stock Information
- Founded
- SB 2007
- ERAS 2018
- Country
- SB Monaco
- ERAS United States
- Employees
- SB N/A
- ERAS N/A
- Industry
- SB Marine Transportation
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- ERAS Health Care
- Exchange
- SB Nasdaq
- ERAS Nasdaq
- Market Cap
- SB 423.6M
- ERAS 484.4M
- IPO Year
- SB 2008
- ERAS 2021
- Fundamental
- Price
- SB $4.24
- ERAS $1.74
- Analyst Decision
- SB Strong Buy
- ERAS Strong Buy
- Analyst Count
- SB 1
- ERAS 6
- Target Price
- SB $5.00
- ERAS $4.83
- AVG Volume (30 Days)
- SB 405.6K
- ERAS 975.9K
- Earning Date
- SB 07-29-2025
- ERAS 08-11-2025
- Dividend Yield
- SB 4.72%
- ERAS N/A
- EPS Growth
- SB N/A
- ERAS N/A
- EPS
- SB 0.67
- ERAS N/A
- Revenue
- SB $290,312,000.00
- ERAS N/A
- Revenue This Year
- SB N/A
- ERAS N/A
- Revenue Next Year
- SB $13.41
- ERAS N/A
- P/E Ratio
- SB $6.32
- ERAS N/A
- Revenue Growth
- SB N/A
- ERAS N/A
- 52 Week Low
- SB $3.02
- ERAS $1.01
- 52 Week High
- SB $5.61
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- SB 67.34
- ERAS 69.28
- Support Level
- SB $3.97
- ERAS $1.66
- Resistance Level
- SB $4.33
- ERAS $1.80
- Average True Range (ATR)
- SB 0.11
- ERAS 0.11
- MACD
- SB 0.03
- ERAS 0.03
- Stochastic Oscillator
- SB 85.00
- ERAS 87.91
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.